Skip to menu Skip to content Skip to footer

Safety of Hendra virus anti-G glycoprotein monoclonal antibody in humans (2012-2013)

Abstract

Hendra virus infection in humans is a serious, and often fatal, disease. No cure exists for Hendra infection and existing treatments are ineffective. Recently, a human monoclonal antibody has shown great promise in protecting animals from developing the disease. This project aims to perform preclinical safety testing and a Phase I clinical trial to establish the safety profile of this antibody such that it can be used to prevent Hendra infection in humans exposed to the disease.

Experts

Professor Peter Gray

Professorial Research Fellow
Australian Institute for Bioengineering and Nanotechnology
Peter Gray
Peter Gray

Emeritus Professor Stephen Mahler

Emeritus Professor
Australian Institute for Bioengineering and Nanotechnology
Stephen Mahler
Stephen Mahler